Bateman Horne Center Deepens the Science Behind Oxaloacetate for ME/CFS and Long COVID

Bateman Horne Center Deepens the Science Behind Oxaloacetate for ME/CFS and Long COVID

The journey toward effective treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID has long been hindered by a lack of objective measurement and translational research grounded in the real-world experience of patients.

The work of the Bateman Horne Center stands out as a beacon of evidence-based hope. This U.S. based research and clinical center is globally recognized for advancing science and care for the millions suffering with ME/CFS.

Two of the Bateman Horne Center’s recent publications highlight exciting new clinical data on oxaloacetate, a key compound under study for improving fatigue and cognition in ME/CFS available as Oxaloacetate CFS.

Understanding the Potential of Oxaloacetate for Long COVID and ME/CFS
In a 2025 forum, Dr. Suzanne Vernon and Jennifer Bell, FNP-C from Bateman Horne Center unpack findings from the REGAIN trial, a randomized, placebo-controlled study examining oxaloacetate’s impact on fatigue and cognition in Long COVID.

Over the course of the 6-week trial, participants taking Oxaloacetate CFS experienced:

  • Significant improvements in cognitive function, including faster reaction times, increased cognitive efficiency, and improved accuracy in tasks requiring focus and decision-making.

  • Significant reductions in symptom burden, as measured by the DePaul Symptom Questionnaire–Short Form (DSQ‑SF), with benefits emerging as early as Day 21 of Oxaloacetate therapy.

Deep Dive: Oxaloacetate for Fatigue Reduction
Bateman Horne Center’s RESTORE ME trial—a 90-day double-blind, placebo-controlled study tested 2,000 mg/day of oxaloacetate in 82 adults with ME/CFS. Results from this study include:

  • A significant reduction in fatigue by an average of 25 to 35%

  • Improvements in both mental and physical fatigue

  • 40.5% of the oxaloacetate group classified as "enhanced responders," with an average fatigue reduction of 63%

Why the Bateman Horne Center’s Research Matters

The Bateman Horne Center is an exemplary treatment clinic and research hub combining data science, wearable technology, and compassionate clinical care for ME/CFS and Long COVID.

Founded by Dr. Lucinda Bateman, a physician who helped establish the 2015 National Academies diagnostic criteria for ME/CFS, Bateman Horne Center unites rigorous clinical trials with patient-reported outcomes and objective measures such as cognitive testing and daily activity tracking.

Read the full data from all Oxaloacetate CFS clinical trials here and review frequently asked questions here.

 

Back to blog